RESEARCH ARTICLES

875  Plasma Adiponectin and Soluble Leptin Receptor and Risk of Colorectal Cancer: A Prospective Study
Mingyang Song, Xuehong Zhang, Kana Wu, Shuji Ogino, Charles S. Fuchs, Edward L. Giovannucci, and Andrew T. Chan

886  Dietary Polyphenols Suppress Elevated Levels of Proinflammatory Mediators and Aromatase in the Mammary Gland of Obese Mice
Kotha Subbaramaiah, Erika Sue, Priya Bhardwaj, Baoheng Du, Clifford A. Hudis, Dilip Giri, Clifford A. Hudis, Dilip Giri, Levy Kopelovich, Xi Kathy Zhou, and Andrew J. Dannenberg

898  Ultrasensitive Detection of Unknown Colon Cancer-Initiating Mutations Using the Example of the Adenomatous Polyposis Coli Gene
Christian Gerecke, Conny Mascher, Uwe Gottschalk, Burkhard Kleuser, and Bettina Scholtka

908  Chemoprevention of Colon and Small Intestinal Tumorigenesis in APCmin/+ Mice By SHetA2 (NSC721689) without Toxicity
Doris Mangiaracina Benbrook, Suresh Gurusingwamy, Yuhong Wang, Zhongjie Sun, Altaf Mohammed, Yuting Zhang, Qian Li, and Chinthalapally V. Rao

917  Examining the Association between Oral Health and Oral HPV Infection
Thanh Cong Bui, Christine M. Markham, Michael Wallis Ross, and Patricia Dolan Mullen

925  Modulation of Circulating Angiogenic Factors and Tumor Biology by Aerobic Training in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

938  An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China

949  Cheliensisin A Inhibits EGF-Induced Cell Transformation with Stabilization of p53 Protein Via a Hydrogen Peroxide/Chk1-Dependent Axis
Jingjie Zhang, Guangxin Gao, Liang Chen, Xu Deng, Jingxia Li, Yonghui Yu, Dongyun Zhang, Fei Li, Min Zhang, Qinshi Zhao, and Chuanshu Huang

959  Oral Administration of a Gemini Vitamin D Analog, a Synthetic Triterpenoid and the Combination Prevents Mammary Tumorigenesis Driven by ErbB2 Overexpression
Jae Young So, Joseph E. Wahler, Tae Sook Yoon, Amanda K. Smolenek, Yong Lin, Weichung Joe Shih, Hubert Maehr, Milan Uskokovic, Karen T. Libby, Michael B. Sporn, and Nanjoo Suh

971  A Randomized Pilot Trial of Dietary Modification for the Chemoprevention of Noninvasive Bladder Cancer: The Dietary Intervention in Bladder Cancer Study

979  Proteomic Changes Induced by Effective Chemopreventive Ratios of n-3:n-6 Fatty Acids and Tamoxifen against MNU-Induced Mammary Cancer in the Rat
Christine G. Skibinski, Henry J. Thompson, Arunangshu Das, Andrea Manni, James D. Bortner, Anne Stanley, Bruce A. Stanley, and Karam El-Bayoumy
Cultivated Sea Lettuce is a Multiorgan Protector from Oxidative and Inflammatory Stress by Enhancing the Endogenous Antioxidant Defense System
Ranjala Ratnayake, Yanxia Liu, Valerie J. Paul, and Hendrik Luesch

Oral Naftopidil Suppresses Human Renal-Cell Carcinoma by Inducing G1 Cell-Cycle Arrest in Tumor and Vascular Endothelial Cells
Yoichi Iwamoto, Kenichiro Ishii, Takeshi Sasaki, Manabu Kato, Hideki Kanda, Yasushi Yamada, Kiminobu Arima, Taizo Shiraishi, and Yoshiki Sugimura

ABOUT THE COVER
Human epidermal growth factor receptor 2 (HER2 or ErbB2), an ErbB receptor tyrosine kinase, is overexpressed in approximately 20% of cases of human breast cancer, and the ErbB2 signaling pathway is a critical therapeutic target for ErbB2-overexpressing breast cancer. The inhibitory effects of the Gemini vitamin D analogue BXL0124, the synthetic triterpenoid CDDO-Im, and the combination on tumorigenesis in MMTV-ErbB2/neu transgenic mice were investigated. All three treatments repressed the activation of ErbB2, which was prominent at the leading edge of mammary tumors and delayed the development of these tumors without significant toxicity. The cover micrograph (400×) depicts the merged images of activated ErbB2 (pErbB2, shown as green), total ErbB2 (red), and nuclei (blue) in untreated MMTV-ErbB2/neu transgenic mice. Therapeutic efficacy was investigated using the combination of BXL0124 and CDDO-Im. Short-term treatment with the combination did not show effects on tumor growth or the ErbB2 signaling pathway. The present study demonstrates that BXL0124, CDDO-Im, and the combination are potential agents for prevention, but not treatment, of the tumorigenesis of ErbB2-overexpressing breast cancer. See article by So and colleagues (beginning on page 959) for more information.